You may not have realized it, but making medicines is a dirty job.
A pair of new reports highlights the point: One finds troubling pollution emanating from plants in India that supply more than two dozen drug makers around the world, while the other underscores a failure by numerous antibiotic makers to disclosure discharges into the environment.
Let’s start with the first report. Interestingly, it was commissioned by a fund manager — Nordea Asset Management, which is a unit of the largest Nordic bank and manages $375 billion in investments, including $6 billion that is invested in the pharmaceutical industry.
About the Author Reprints
May I observe that US-FDA can inspect for compliance with the cGMPs (Current Good Manufacturing Practices) which are US federal regulations. They get enough push back about ‘where is that in the regulations’ without adding environmental issues. Those are covered in the US (or nowadays, perhaps not) by the US EPA. I am not aware of the EPS working to ever do foreign inspections but I may be wrong – that does happen often.